Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Katiyar, Samiksha ^a   Kufareva, Irina ^b   Behera, Ranjan ^a   Thomas, Sarah M ^a   Ogata, Yuko ^d   Pollastri, Michael ^c   Abagyan, Ruben ^b   Mensa Wilmot, Kojo ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; ANTITRYPANOSOMAL AGENT; BINDING PROTEIN; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; VASCULOTROPIN;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CELL LYSATE; DRUG BINDING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TARGETING; SEQUENCE ALIGNMENT; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMIASIS;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; CHROMATOGRAPHY, AFFINITY; HELA CELLS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; MORPHOLINES; NAD; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PURINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURAL HOMOLOGY, PROTEIN; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84874263173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056150     Document Type: Article

References (74)

1. Barrett MP, Boykin DW, Brun R, Tidwell RR, (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152: 1155-1171.
2. Brun R, Balmer O, (2006) New developments in human African trypanosomiasis. Curr Opin Infect Dis 19: 415-420.
3. Sessa G, Raz V, Savaldi S, Fluhr R, (1996) PK12, a plant dual-specificity protein kinase of the LAMMER family, is regulated by the hormone ethylene. Plant Cell 8: 2223-2234.
4. Kentrup H, Becker W, Heukelbach J, Wilmes A, Schurmann A, et al. (1996) Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. J Biol Chem 271: 3488-3495.
5. Letwin K, Mizzen L, Motro B, Ben-David Y, Bernstein A, et al. (1992) A mammalian dual specificity protein kinase, Nek1, is related to the NIMA cell cycle regulator and highly expressed in meiotic germ cells. EMBO J 11: 3521-3531.
6. Parker LL, Atherton-Fessler S, Piwnica-Worms H, (1992) p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. Proc Natl Acad Sci U S A 89: 2917-2921.
7. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
8. Chen R, Gandhi V, Plunkett W, (2006) A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 66: 10959-10966.
9. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
10. Weinstein IB, Joe AK, (2006) Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
11. Lackey KE, (2006) Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Top Med Chem 6: 435-460.
12. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, et al. (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64: 4931-4941.
13. Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, et al. (2010) AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Exp Hematol.
14. Slichenmyer WJ, Elliott WL, Fry DW, (2001) CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28: 80-85.
15. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, et al. (2009) A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 64: 1139-1148.
16. Trinks C, Djerf EA, Hallbeck AL, Jonsson JI, Walz TM, (2010) The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells. Biochem Biophys Res Commun 393: 6-10.
17. Nett IR, Martin DM, Miranda-Saavedra D, Lamont D, Barber JD, et al. (2009) The phosphoproteome of bloodstream form trypanonosoma brucei, causative agent of African sleeping sickness. Mol Cell Proteomics.
18. Nett IR, Davidson L, Lamont D, Ferguson MA, (2009) Identification and specific localization of tyrosine-phosphorylated proteins in Trypanosoma brucei. Eukaryot Cell 8: 617-626.
19. Parsons M, Worthey EA, Ward PN, Mottram JC, (2005) Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 6: 127.
20. Lochhead PA, Sibbet G, Kinstrie R, Cleghon T, Rylatt M, et al. (2003) dDYRK2: a novel dual-specificity tyrosine-phosphorylation-regulated kinase in Drosophila. Biochem J 374: 381-391.
21. Lim WA, Pawson T, (2010) Phosphotyrosine signaling: evolving a new cellular communication system. Cell 142: 661-667.
22. Wheeler-Alm E, Shapiro SZ, (1992) Evidence of Tyrosine Kinase Activity in the Protozoan Parasite Trypanosoma brucei JProtozool. 39: 413-416.
23. Hamadien M, Bakhiet M, Harris RA, (2000) Interferon-gamma induces secretion of trypanosome lymphocyte triggering factor via tyrosine protein kinases. Parasitology 120 (Pt 3): 281-287.
24. Subramanya S, Mensa-Wilmot K, (2010) Diacylglycerol-stimulated endocytosis of transferrin in trypanosomatids is dependent on tyrosine kinase activity. PLoS One 5: e8538.
25. Subramanya S, Hardin CF, Steverding D, Mensa-Wilmot K, (2009) Glycosylphosphatidylinositol-specific phospholipase C regulates transferrin endocytosis in the African trypanosome. Biochem J 417: 685-694.
26. Hirumi H, Hirumi K, (1994) Axenic culture of African trypanosome bloodstream forms. ParasitolToday 10: 80-84.
27. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, et al. (2009) Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28: 4249-4260.
28. Deutsch EW, Mendoza L, Shteynberg D, Farrah T, Lam H, et al. (2010) A guided tour of the Trans-Proteomic Pipeline. Proteomics 10: 1150-1159.
29. Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, et al. (2006) Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 5: 112-121.
30. Higdon R, Hogan JM, Kolker N, van Belle G, Kolker E, (2007) Experiment-specific estimation of peptide identification probabilities using a randomized database. OMICS 11: 351-365.
31. Myers T, Law W, Eng JK, McIntosh M (2007) Installation and use of the Computational Proteomics Analysis System (CPAS). Curr Protoc Bioinformatics Chapter 13: Unit 13 15.
32. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib). Cancer Res 64: 6652-6659.
33. Kufareva I, Rueda M, Katritch V, participants GD, Stevens RC, et al. (2011) Status of GPCR modeling and docking as reflected by community wide GPCR Dock 2010 assessment. Structure accepted.
34. Abagyan R, Batalov S, Cardozo T, Totrov M, Webber J, et al. (1997) Homology modeling with internal coordinate mechanics: deformation zone mapping and improvements of models via conformational search. Proteins Suppl 1: 29-37.
35. Rost B, (1999) Twilight zone of protein sequence alignments. Protein Eng 12: 85-94.
36. Abagyan RA, Totrov MM, Kuznetsov DA, (1994) Icm: A New Method For Protein Modeling and Design: Applications To Docking and Structure Prediction From The Distorted Native Conformation. J Comp Chem 15: 488-506.
37. Abagyan R, Totrov M, (1994) Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. Journal of molecular biology 235: 983-1002.
38. Arnautova YA, Abagyan RA, Totrov M, (2010) Development of a new physics-based internal coordinate mechanics force field and its application to protein loop modeling. Proteins: Structure, Function, and Bioinformatics 79: 477-498.
39. Laskowski RA, MacArthur MW, Moss DS, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures,. J Appl Cryst 26: 283-291.
40. Schapira M, Totrov M, Abagyan R, (1999) Prediction of the binding energy for small molecules, peptides and proteins. Journal of Molecular Recognition 12: 177-190.
41. Schell D, Borowy NK, Overath P, (1991) Transferrin is a growth factor for the bloodstream form of Trypanosoma brucei. Parasitol Res 77: 558-560.
42. Burris HA, 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305-5313.
43. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, et al. (2007) Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13: 4209-4217.
44. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R, (2006) Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12: 4441s-4445s.
45. Arora A, Scholar EM, (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979.
46. Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, et al. (2001) Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem 44: 429-440.
47. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, et al. (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263.
48. Kim JW, Kim HP, Im SA, Kang S, Hur HS, et al. (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272: 296-306.
49. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, et al. (2005) The Genome of the African Trypanosome Trypanosoma brucei. Science 309: 416-422.
50. Panigrahi AK, Ogata Y, Zikova A, Anupama A, Dalley RA, et al. (2009) A comprehensive analysis of Trypanosoma brucei mitochondrial proteome. Proteomics 9: 434-450.
51. Gafken PR (2009) An overview of the qualitative analysis of phosphoproteins by mass spectrometry. Methods in molecular biology 527: 159-172, ix.
52. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease. Science 309: 409-415.
53. Li Z, Umeyama T, Wang CC, (2008) The chromosomal passenger complex and a mitotic kinesin interact with the Tousled-like kinase in trypanosomes to regulate mitosis and cytokinesis. PLoS One 3: e3814.
54. Li Z, Lee JH, Chu F, Burlingame AL, Gunzl A, et al. (2008) Identification of a novel chromosomal passenger complex and its unique localization during cytokinesis in Trypanosoma brucei. PLoS One 3: e2354.
55. Urbaniak MD, (2009) Casein kinase 1 isoform 2 is essential for bloodstream form Trypanosoma brucei. Mol Biochem Parasitol 166: 183-185.
56. Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, et al. (2008) Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother 52: 3710-3717.
57. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 26: 127-132.
58. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
59. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. Cancer Cell 11: 217-227.
60. Johnson LN, (2009) Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 42: 1-40.
61. Calvo E, Tolcher AW, Hammond LA, Patnaik A, de Bono JS, et al. (2004) Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res 10: 7112-7120.
62. Park YW, Younes MN, Jasser SA, Yigitbasi OG, Zhou G, et al. (2005) AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 11: 1963-1973.
63. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, et al. (2003) Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 46: 49-63.
64. Vema A, Panigrahi SK, Rambabu G, Gopalakrishnan B, Sarma JA, et al. (2003) Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies. Bioorg Med Chem 11: 4643-4653.
65. Hubbard RD, Dickerson SH, Emerson HK, Griffin RJ, Reno MJ, et al. (2008) Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines. Bioorg Med Chem Lett 18: 5738-5740.
66. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, et al. (2005) Cellular targets of gefitinib. Cancer Res 65: 379-382.
67. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044.
68. Duncan JS, Haystead TA, Litchfield DW, (2012) Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP. Methods Mol Biol 795: 119-134.
69. Haystead TA, (2006) The purinome, a complex mix of drug and toxicity targets. Curr Top Med Chem 6: 1117-1127.
70. Walter SA, Cutler RE Jr, Martinez R, Gishizky M, Hill RJ, (2003) Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue. J Biol Chem 278: 18221-18228.
71. Kaouass M, Audette M, Ramotar D, Verma S, De Montigny D, et al. (1997) The STK2 gene, which encodes a putative Ser/Thr protein kinase, is required for high-affinity spermidine transport in Saccharomyces cerevisiae. Mol Cell Biol 17: 2994-3004.
72. Goldammer T, Brunner RM, Kata SR, Womack JE, (2006) Assignment of the bovine receptor-interacting serine-threonine kinase 2 gene (RIPK2) to BTA14 with somatic and radiation cell hybrids. Cytogenet Genome Res 112: 341C.
73. Roskoski R Jr, (2004) Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 324: 1155-1164.
74. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, et al. (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. The Journal of biological chemistry 279: 55827-55832.